Literature DB >> 15277225

The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Rosa Marina Melillo1, Anna Maria Cirafici, Valentina De Falco, Marie Bellantoni, Gennaro Chiappetta, Alfredo Fusco, Francesca Carlomagno, Antonella Picascia, Donatella Tramontano, Giovanni Tallini, Massimo Santoro.   

Abstract

Activating germ-line point mutations in the RET receptor are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma (MTC), whereas somatic RET rearrangements are prevalent in papillary thyroid carcinomas (PTCs). Some rare kindreds, carrying point mutations in RET, are affected by both cancer types, suggesting that, under specific circumstances, point mutations in RET can drive the generation of PTC. Here we describe a family whose siblings, affected by both PTC and MTC, carried a germ-line point mutation in the RET extracellular domain, converting cysteine 634 into serine. We tested on thyroid follicular cells the transforming activity of RET(C634S), RET(K603Q), another mutant identified in a kindred with both PTC and MTC, RET(C634R) a commonly isolated allele in MEN2A, RET(M918T) responsible for MEN2B and also identified in kindreds with both PTC and MTC, and RET/PTC1 the rearranged oncogene that characterizes bona fide PTC in patients without MTC. We show that the various RET point mutants, but not wild-type RET, scored constitutive kinase activity and exerted mitogenic effects for thyroid PC Cl 3 cells, albeit at significantly lower levels compared to RET/PTC1. The low mitogenic activity of RET point mutants paralleled their reduced kinase activity compared to RET/PTC. Furthermore, RET point mutants maintained a protein domain, the intracellular juxtamembrane domain, that exerted negative effects on the mitogenic activity. In conclusion, RET point mutants can behave as dominant oncogenes for thyroid follicular cells. Their transforming activity, however, is rather modest, providing a possible explanation for the rare association of MTC with PTC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15277225      PMCID: PMC1618571          DOI: 10.1016/S0002-9440(10)63316-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line.

Authors:  M Santoro; R M Melillo; M Grieco; M T Berlingieri; G Vecchio; A Fusco
Journal:  Cell Growth Differ       Date:  1993-02

2.  Thyroid cancer: pathologic and natural history.

Authors:  E D Williams
Journal:  Recent Results Cancer Res       Date:  1980

3.  Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.

Authors:  S Ito; T Iwashita; N Asai; H Murakami; Y Iwata; G Sobue; M Takahashi
Journal:  Cancer Res       Date:  1997-07-15       Impact factor: 12.701

4.  Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells.

Authors:  S J Holland; N W Gale; G D Gish; R A Roth; Z Songyang; L C Cantley; M Henkemeyer; G D Yancopoulos; T Pawson
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

5.  Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.

Authors:  E Vigna; D Gramaglia; P Longati; A Bardelli; P M Comoglio
Journal:  Oncogene       Date:  1999-07-22       Impact factor: 9.867

6.  Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.

Authors:  A Pasini; O Geneste; P Legrand; M Schlumberger; M Rossel; L Fournier; B B Rudkin; I Schuffenecker; G M Lenoir; M Billaud
Journal:  Oncogene       Date:  1997-07-24       Impact factor: 9.867

7.  The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.

Authors:  M Santoro; R Rosati; M Grieco; M T Berlingieri; G L D'Amato; V de Franciscis; A Fusco
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

8.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.

Authors:  M Santoro; F Carlomagno; A Romano; D P Bottaro; N A Dathan; M Grieco; A Fusco; G Vecchio; B Matoskova; M H Kraus
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

9.  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas.

Authors:  S M Jhiang; J E Sagartz; Q Tong; J Parker-Thornburg; C C Capen; J Y Cho; S Xing; C Ledent
Journal:  Endocrinology       Date:  1996-01       Impact factor: 4.736

10.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

Authors:  J A Fagin; K Matsuo; A Karmakar; D L Chen; S H Tang; H P Koeffler
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

View more
  6 in total

1.  Papillary thyroid carcinoma and multiple endocrine neoplasia type 2.

Authors:  B Febrero; J M Rodríguez; A Ríos; P Portillo; P Parrilla
Journal:  J Endocrinol Invest       Date:  2015-04-23       Impact factor: 4.256

2.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors: 
Journal:  J Clin Invest       Date:  2016-04-01       Impact factor: 14.808

Review 3.  On the Origin of Cells and Derivation of Thyroid Cancer: C Cell Story Revisited.

Authors:  Mikael Nilsson; Dillwyn Williams
Journal:  Eur Thyroid J       Date:  2016-06-24

Review 4.  RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Authors:  Andrea Z Lai; Taranjit S Gujral; Lois M Mulligan
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

5.  A case of Warthin-like papillary thyroid carcinoma with diffuse sclerosing stroma and a novel RET mutation: a new entity or a combined tumour?

Authors:  Fausto Maffini; Daniele Lorenzini; Daniela Lepanto; Elvio De Fiori; Caterina Fumagalli; Alessandra Rappa; Marta Tagliabue; Massimo Barberis
Journal:  Ecancermedicalscience       Date:  2019-10-02

6.  A unique RET EXON 11 (G691S) polymorphism in an Indian patient with a collision tumor of the thyroid.

Authors:  Bharat Rekhi; Rakesh R Badhe; Maria Alina Desouza; Devendra Chaukar; Anil K D'Cruz; Suprita Arya; S V Kane
Journal:  Diagn Pathol       Date:  2007-10-16       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.